Liraglutide in Preventing Delirium in Diabetic Elderly After Cardiac Surgery
Recruiting · NCT06361238 · Interventional (participants receive a specific treatment) · Lead sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
View the official record on ClinicalTrials.gov →Interventions studied
Liraglutide injectionPlacebo injection
What this trial is about
This study aims to clarify the preventive effect of perioperative liraglutide application on postoperative delirium in elderly patients with Type 2 diabetes undergoing cardiac surgery.
Who can take part
Age range
60 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 3
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Age ≥ 60 years
- Type 2 diabetes
- Patients undergoing elective cardiac surgery
Exclusion criteria
- History of neurological or psychiatric disorders, such as schizophrenia, epilepsy, Parkinson's disease, severe dementia, etc
- Patients with communication difficulties, such as severe visual, auditory, or speech impairments
- History of central nervous system damage or surgery
- Cardiac function NYHA Class IV
- Severe liver dysfunction (Child-Pugh Class C)
- Severe renal failure requiring renal replacement therapy
- History of pancreatitis
- Type 1 diabetes
- Patients whose blood sugar is difficult to control within 4-8 mmol/L during the screening period
- Patients with medullary thyroid carcinoma or a family history of it
- Pregnant or breastfeeding women
- Intolerance or allergy to liraglutide
- Previous use of GLP-1A and SGLT2i
- Patients who refuse to sign the informed consent
Where it is running
1 location listed.
- Wenxue liu - Nanjing, Jiangsu, China